Lisaftoclax
Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively[1].
Product Specifications
CAS Number
[2180923-05-9]
Product Name Alternative
APG-2575; Bcl-2/Bcl-xl inhibitor 1
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bcl-2-bcl-xl-inhibitor-1.html
Purity
99.28
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NS(=O)(C1=CC=C(NC[C@@H]2OCCOC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC(CC5)=C(C6=CC=C(Cl)C=C6)CC75CCC7)CC4)C=C3OC8=CN=C(NC=C9)C9=C8
Molecular Formula
C45H48ClN7O8S
Molecular Weight
882.42
Precautions
H302, H315, H319
References & Citations
[1]WANG, Chia, et al. N- (PHENYLSULFONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS. Patent. WO2018027097A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Bcl-2; Bcl-xL
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human GPR19 shRNA (UAS) - Lentiviral human GPR19 shRNA (UAS) (25)